1. European Medicines Agency [EMA]. Biosimilar medicines. London: EMA; 2013. http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/document_listing/document_listing_000318.jsp&mid=WC0b01ac0580281bf0 . Accessed 28 April 2015.
2. European Medicines Agency [EMA]. Questions and answers on biosimilar medicines (similar biological medicinal products) [document reference EMA/837805/2011]. London: EMA; 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500020062.pdf . Accessed 8 Jan 2016.
3. US Food and Drug Administration [FDA]. Biosimilars. Silver Spring: FDA; 2015. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/default.htm . Accessed 14 Sept 2015.
4. Mestre-Ferrandiz J, Towse A. What is the role of HTA for biosimilars? [briefing no. 54]. London: Office of Health Economics; 2014. https://www.ohe.org/publications/what-role-hta-biosimilars . Accessed 8 Jan 2016.
5. Grabowski HG, Ridley DB, Schulman KA. Entry and competition in generic biologicals. Manag Decis Econ. 2007;28(4–5):439–51.